Stock Track | Harrow Health Soars 5.95% as CMS Approves Transitional Pass-Through Status for Triesence

Stock Track03-24 13:42

Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory approval for its product Triesence. The surge comes after the Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Harrow's Triesence 40 mg/ml.

According to the announcement, Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This approval marks a crucial milestone for Harrow Health, as it potentially opens up new revenue streams and market opportunities for the company.

The transitional pass-through status is expected to enhance the accessibility of Triesence to patients and potentially boost its adoption in medical settings. This development could significantly impact Harrow Health's financial outlook, as improved reimbursement often leads to increased product utilization. Investors appear to be reacting positively to this news, viewing it as a catalyst for potential growth in Harrow's market share and profitability in the ophthalmic pharmaceutical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126330846?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-24 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126330846","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Soars 5.95% as CMS Approves Transitional Pass-Through Status for Triesence","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory approval for its product Triesence. The surge comes after the Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Harrow's Triesence 40 mg/ml.</p>\n\n<p>According to the announcement, Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This approval marks a crucial milestone for Harrow Health, as it potentially opens up new revenue streams and market opportunities for the company.</p>\n\n<p>The transitional pass-through status is expected to enhance the accessibility of Triesence to patients and potentially boost its adoption in medical settings. This development could significantly impact Harrow Health's financial outlook, as improved reimbursement often leads to increased product utilization. Investors appear to be reacting positively to this news, viewing it as a catalyst for potential growth in Harrow's market share and profitability in the ophthalmic pharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Soars 5.95% as CMS Approves Transitional Pass-Through Status for Triesence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Soars 5.95% as CMS Approves Transitional Pass-Through Status for Triesence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-24 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory approval for its product Triesence. The surge comes after the Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Harrow's Triesence 40 mg/ml.</p>\n\n<p>According to the announcement, Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This approval marks a crucial milestone for Harrow Health, as it potentially opens up new revenue streams and market opportunities for the company.</p>\n\n<p>The transitional pass-through status is expected to enhance the accessibility of Triesence to patients and potentially boost its adoption in medical settings. This development could significantly impact Harrow Health's financial outlook, as improved reimbursement often leads to increased product utilization. Investors appear to be reacting positively to this news, viewing it as a catalyst for potential growth in Harrow's market share and profitability in the ophthalmic pharmaceutical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1126330846","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126330846","pubTimestamp":1742823742,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc  stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory approval for its product Triesence. The surge comes after the Centers for Medicare & Medicaid Services  granted transitional pass-through status for Harrow's Triesence 40 mg/ml.According to the announcement, Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center  and Hospital Outpatient Department  settings starting from April 2025. This approval marks a cruci","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"随着CMS批准Triesence的过渡传递状态，Harrow Health股价飙升5.95%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) stock is soaring 5.95% in pre-market trading on Monday, following a significant regulatory approval for its product Triesence. The surge comes after the Centers for Medicare & Medicaid Services (CMS) granted transitional pass-through status for Harrow's Triesence 40 mg/ml.\nAccording to the announcement, Triesence will be eligible for separate reimbursement in Ambulatory Surgery Center (ASC) and Hospital Outpatient Department (HOPD) settings starting from April 2025. This approval marks a crucial milestone for Harrow Health, as it potentially opens up new revenue streams and market opportunities for the company.\nThe transitional pass-through status is expected to enhance the accessibility of Triesence to patients and potentially boost its adoption in medical settings. This development could significantly impact Harrow Health's financial outlook, as improved reimbursement often leads to increased product utilization. Investors appear to be reacting positively to this news, viewing it as a catalyst for potential growth in Harrow's market share and profitability in the ophthalmic pharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126330846"}